United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read General business news Will PEDEVCO Corp.’s 1-for-20 reverse split strengthen its institutional appeal? (NYSE American: PED) PEDEVCO Corp. executes a 1-for-20 reverse stock split after its Juniper merger. Discover what this means for investors and capital strategy. bySoujanya RaviMarch 3, 2026